By Andi Anderson
NutriQuest has announced a partnership with Modulant Biosciences to advance research on controlling Porcine Reproductive and Respiratory Syndrome (PRRSv) and other swine diseases.
Modulant Biosciences, based in Indiana, has discovered a small molecule capable of fighting PRRSv, a virus that costs the U.S. pork industry approximately $1.2 billion annually.
This partnership aims to accelerate the development of this promising drug candidate, providing a long-awaited solution to a problem that has challenged swine producers since the 1980s.
Dr. Tom Campi, CEO of Modulant Biosciences, expressed optimism about the collaboration, stating that it will help identify the best molecule for treating PRRSv, giving the industry a critical tool for disease control.
The partnership will also explore treatments for other significant swine diseases like Porcine Epidemic Diarrhea virus (PEDv) and Swine Influenza virus (SIV). Additionally, there is potential for the technology to be applied in poultry and ruminant health.
NutriQuest CEO Steve Weiss highlighted the importance of the partnership, noting that it not only addresses key challenges for swine producers but also expands NutriQuest’s expertise in regulated drug development. This collaboration opens the door for future innovations in animal health.
Modulant Biosciences’ approach focuses on targeting host cell processes essential for viral replication, a novel strategy that offers the animal health industry more cost-effective and effective disease control therapies.
NutriQuest’s research and development team, led by Dr. Kim Friesen, is eager to bring this innovation to life and make meaningful improvements to swine health.
This partnership begins immediately, with initial efforts directed toward PRRSv disease treatment. The combined expertise of both organizations presents a significant opportunity to transform swine disease management and create new advancements in animal health.
Photo Credit: gettyimages-seastock
Categories: Indiana, Livestock, Hogs